Vertex Pharmaceuticals Incorporated (VRTX) stock is down -29.52% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives VRTX stock a score of 30 out of a possible 100.
That rank is chiefly influenced by a long-term technical score of 7. VRTX's rank also includes a short-term technical score of 10. The fundamental score for VRTX is 73. In addition to the average rating from Wall Street analysts, VRTX stock has a mean target price of $263.62. This means analysts expect the stock to increase 41.67% over the next 12 months.
VRTX has an Overall Score of 30. Find out what this means to you and get the rest of the rankings on VRTX!
Vertex Pharmaceuticals Incorporated (VRTX) stock is higher by 0.22% while the S&P 500 is up 0.1% as of 2:12 PM on Tuesday, Sep 21. VRTX is up $0.41 from the previous closing price of $185.67 on volume of 496,658 shares. Over the past year the S&P 500 is higher by 32.95% while VRTX is down -29.52%. VRTX earned $7.59 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 24.53.
Click Here to get the full Stock Report for Vertex Pharmaceuticals Incorporated stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
